Get Quote

Human Genome Sciences (NASDAQ:HGSI.DL)

CAPS Game Rating: No stars

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.

Recs

0
Member Avatar HunNemo (62.41) Submitted: 26/09/2011 07:18:26 : Outperform Start Price: $14.31 HGSI.DL Score: -19.71

healing people is good business

Report this Post Reply

For details about CAPS-UK, and the conditions you agree to be bound by, please see our Terms and Conditions.